AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,042.00p
   
  • Change Today:
    -164.00p
  • 52 Week High: 13,276.00p
  • 52 Week Low: 9,501.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.29m
  • Volume: 2,329,887
  • Market Cap: £171,184m
  • RiskGrade: 123

AstraZeneca reports positive results from blood cancer drug trial

By Benjamin Chiou

Date: Thursday 02 May 2024

LONDON (ShareCast) - (Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.
Interim analysis of the ECHO Phase III trial shows that Calquence, otherwise known as acalabrutinib - when used with a combination of standard-of-care chemoimmunotherapy, bendamustine and rituximab - demonstrated a "statistically significant and clinically meaningful improvement in progression-free survival versus standard of care in previously untreated adult patients with mantle cell lymphoma".

Mantle cell lymphoma or MCL, which is estimated to affect just 27,500 people worldwide, is a rare and aggressive form of non-Hodgkin lymphoma that sees B-lymphocytes mutate into malignant cells within a region of the lymph node known as the mantle zone.

Principal investigator in the trial, Michael Wang, who works at the MD Anderson Cancer Center in Houston, said the positive progression-free survival results "could provide a new standard of care for patients with MCL".

Data from the trial will be now shared with global regulatory authorities, and Calquence is now being evaluated alone and in combination for the treatment of multiple B-cell blood cancers.

"These impactful results in mantle cell lymphoma show that bringing Calquence to the first-line setting significantly delays disease progression and, for the first time, shows potential to extend survival," said Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca.

"The improvement in progression-free survival together with the differentiated safety profile of Calquence are both important as we strive to transform outcomes earlier in the course of disease treatment."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,042.00p
Change Today -164.00p
% Change -1.46 %
52 Week High 13,276.00p
52 Week Low 9,501.00p
Volume 2,329,887
Shares Issued 1,550.29m
Market Cap £171,184m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.03% below the market average92.03% below the market average92.03% below the market average92.03% below the market average92.03% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
6.17% above the market average6.17% above the market average6.17% above the market average6.17% above the market average6.17% above the market average
51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average
Income
88.49% below the market average88.49% below the market average88.49% below the market average88.49% below the market average88.49% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average
Growth
88.65% above the market average88.65% above the market average88.65% above the market average88.65% above the market average88.65% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 31-Oct-2024

Time Volume / Share Price
16:09 179,211 @ 11,160.00p
16:51 488 @ 11,042.00p
16:51 142 @ 11,042.00p
16:35 3,725 @ 11,042.00p
16:35 75 @ 11,042.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page